Literature DB >> 7503095

Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.

F Stéphan1, M C Etienne, C Wallays, G Milano, F Clergue.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7503095     DOI： 10.1016/s0002-9343(99)80259-9

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  5 in total

Review 1.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

2.  High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy.

Authors:  K H Yeh; A L Cheng
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.

Authors:  H L McLeod; J Sludden; G I Murray; R A Keenan; A I Davidson; K Park; M Koruth; J Cassidy
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

4.  Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.

Authors:  A B Van Kuilenburg; H van Lenthe; M J Blom; E P Mul; A H Van Gennip
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

5.  Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.

Authors:  J G Maring; A B P van Kuilenburg; J Haasjes; H Piersma; H J M Groen; D R A Uges; A H Van Gennip; E G E De Vries
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.